<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025592</url>
  </required_header>
  <id_info>
    <org_study_id>2021KT83</org_study_id>
    <nct_id>NCT05025592</nct_id>
  </id_info>
  <brief_title>cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC</brief_title>
  <official_title>Conventional Transarterial Chemoembolization (cTACE) or Transarterial Chemoembolization (DEB-TACE) +HAIC Combined With Regorafenib ± Anti-PD1 Antibody for Unresected Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE)&#xD;
      or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy&#xD;
      (HAIC) combined with regorafenib and anti-PD-1 antibody or not for unresected hepatocellular&#xD;
      carcinoma (uHCC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, open, single-arm clinical study. Patients receive&#xD;
      cTACE/DEB-TACE+HAIC treatment( 6-8 weeks as a cycle) and regorafenib and anti-PD1 antibody or&#xD;
      not until the disease progresses, intolerable toxicity occurs, the patient is lost to&#xD;
      follow-up or death, or situations other judged by researchers which treatment should be&#xD;
      stopped.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate, ORR</measure>
    <time_frame>6 months</time_frame>
    <description>The objective response rate (ORR) was defined as the complete response (CR) rate + the partial response (PR) rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free overall survival，PFS</measure>
    <time_frame>12 months</time_frame>
    <description>PFS was defined as the interval between the time at which treatment was initiated and intrahepatic tumor and/or extrahepatic tumor progression, symptomatic progression, including massive ascites and liver function that was categorized as Child-Pugh grade C, or death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival，OS</measure>
    <time_frame>24 months</time_frame>
    <description>overall survival (OS) was defined as the interval between the time at which treatment was initiated and death or the last follow-up assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate, DCR</measure>
    <time_frame>6 months</time_frame>
    <description>disease control rate (DCR) was defined as the CR rate + the PR rate + the stable disease (SD) rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HCC</condition>
  <condition>Transarterial Chemoembolization</condition>
  <condition>Hepatic Arterial Infusion Chemotherapy</condition>
  <condition>Regorafenib</condition>
  <arm_group>
    <arm_group_label>cTACE/DEB-TACE-HAIC+regorafenib±anti-PD1 antibody</arm_group_label>
    <description>patients will receive the combination treatment of cTACE/DEB-TACE plus HAIC and combined with regorafenib and anti-PD1 antibody or not. The anti-PD-1 antibody will be used depended on the contraindications or wishes of patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not</description>
    <arm_group_label>cTACE/DEB-TACE-HAIC+regorafenib±anti-PD1 antibody</arm_group_label>
    <other_name>anti-PD1 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cTACE/DEB-TACE-HAIC</intervention_name>
    <description>conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion</description>
    <arm_group_label>cTACE/DEB-TACE-HAIC+regorafenib±anti-PD1 antibody</arm_group_label>
    <other_name>conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with unresectable hepatocellular carcinoma are fail for fisrt line&#xD;
        treatment((including but not limited to sorafenib, levatinib, atelizumab combined with&#xD;
        bevacizumab, etc.) and will received cTACE/DEB-TACE plus HAIC and regorafenib and anti-PD1&#xD;
        antibody or not.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate and sign the informed consent in writing;&#xD;
&#xD;
          2. Age: 18-75 years old;&#xD;
&#xD;
          3. No gender limit;&#xD;
&#xD;
          4. Unresectable hepatocellular carcinoma with clear pathological diagnosis or clinical&#xD;
             diagnosis;&#xD;
&#xD;
          5. Unresectable hepatocellular carcinoma patients who failed first-line treatment&#xD;
             (including but not limited to sorafenib, lenvatinib, atezolizumab combined with&#xD;
             bevacizumab, etc.);&#xD;
&#xD;
          6. At least one measurable lesion (according to mRECIST criteria) imaging diagnosis time&#xD;
             ≤ 21 days from selection;&#xD;
&#xD;
          7. Child-pugh grade A-B7 grade&#xD;
&#xD;
          8. The expected survival period is ≥3 months;&#xD;
&#xD;
          9. General physical condition (ECOG) 0-2;&#xD;
&#xD;
         10. Sufficient bone marrow hematopoietic function (within 7 days): hemoglobin ≥9 g/dL,&#xD;
             white blood cells ≥3.0×10^9/L, neutrophils ≥1.5x 10^9/L, platelets ≥80x 10^9/L; liver&#xD;
             and kidney functions are normal; (Within 14 days): TBIL≤1.5 times the upper limit of&#xD;
             normal; ALT and AST≤5 times the upper limit of normal; creatinine≤1.5 times the upper&#xD;
             limit of normal; INR≤1.7 or prolonged PT≤4s.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who are currently receiving other effective treatments;&#xD;
&#xD;
          2. Patients who have received regorafenib in the past;&#xD;
&#xD;
          3. Patients who have participated in other clinical trials within 4 weeks before&#xD;
             enrollment;&#xD;
&#xD;
          4. Unable to cooperate with cTACE and HAIC treatment;&#xD;
&#xD;
          5. Patients with primary malignant tumors other than hepatocellular carcinoma at the same&#xD;
             time, except for cured skin basal cell carcinoma and cervical carcinoma in situ;&#xD;
&#xD;
          6. Clinically significant cardiovascular diseases, such as heart failure (NYHA III-IV),&#xD;
             uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, uncontrolled&#xD;
             hypertension or a history of myocardial infarction within the past 1 year;&#xD;
&#xD;
          7. Neurological or mental abnormalities that affect cognitive ability, including central&#xD;
             nervous system transfer;&#xD;
&#xD;
          8. There were active serious clinical infections (&gt;grade 2 NCI-CTCAE version 4.0),&#xD;
             including active tuberculosis within 14 days before enrollment;&#xD;
&#xD;
          9. Known or self-reported HIV infection;&#xD;
&#xD;
         10. Uncontrolled systemic diseases, such as poorly controlled diabetes;&#xD;
&#xD;
         11. Known to have hypersensitivity or allergic reactions to any component of the study&#xD;
             drug;&#xD;
&#xD;
         12. Pregnancy (determined by serum β-chorionic gonadotropin test) or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Zhu Xu</investigator_full_name>
    <investigator_title>Hospital Chief Physician，MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

